摘要
胆道恶性肿瘤(BTC)是一种增殖与侵袭性较强、恶性和度较高、预后较差的消化系统肿瘤,受解剖位置特殊、发病隐匿等因素影响,多数患者就诊时已无法通过手术根治,其中位生存期<1年,严重威胁患者生命,也给家庭及社会带来巨大的负担。索拉非尼是一种具有分子靶向的抗肿瘤药物,可靶向作用于肿瘤细胞及血管内皮细胞上的多个位点,对肿瘤组织生长、增殖过程进行抑制,并能诱导细胞凋亡,在BTC治疗中效果显著,为患者改善预后带来了新的可能。但治疗过程中机体产生的耐药性在一定程度上限制了索拉非尼疗效的发挥,这也是未来临床亟须解决的重点与难点问题。
Biliary tract cancer(BTC)is a kind of digestive system tumor with strong proliferation and invasion,high malignancy,and poor prognosis.Affected by factors such as special anatomical location and hidden onset,most patients can no longer be radically cured by surgery at the time of treatment,and the median survival time<1 year,which seriously threatens the life of patients,and also brings a huge burden to the family and society.Sorafenib is an anti-tumor drug with molecular targeting,which can target multiple sites on tumor cells and vascular endothelial cells,inhibit the growth and proliferation process of tumor tissue,and induce cells apoptosis.It has significant efficacy in BTC treatment,which brings new possibilities for improving patient prognosis.However,the drug resistance produced by the body in the course of treatment limits the efficacy of Sorafenib to a certain extent,which is also a key and difficult problem to be solved in future clinical.
作者
姜哲康
王高卿
高过
陆知非
华永飞
JIANG Zhekang;WANG Gaoqing;GAO Guo;LU Zhifei;HUA Yongfei(Department of Hepatobiliary and Pancreatic Surgery,Li Huili Hospital Affiliated to Ningbo University,Zhejiang Province,Ningbo 315000,China)
出处
《中国医药导报》
CAS
2024年第11期193-195,共3页
China Medical Herald
基金
浙江省卫生健康委员会卫生健康科技计划项目(2022KY 1077)。
